Skip to main content
ImmuneOncia Therapeutics, Inc. logo

ImmuneOncia Therapeutics, Inc. — Investor Relations & Filings

Ticker · 424870 ISIN · KR7424870004 KO Manufacturing
Open in API
Filings indexed 54 across all filing types
Latest filing 2026-05-27 Major Shareholding Noti…
Country KR South Korea
Listing KO 424870

About ImmuneOncia Therapeutics, Inc.

http://www.immuneoncia.com/immun/

ImmuneOncia Therapeutics, Inc. is a biopharmaceutical company specializing in the development of innovative immuno-oncology therapeutics. Established in 2016 as a joint venture between Yuhan Corporation and Sorrento Therapeutics, the company focuses on creating novel antibody-based drugs for cancer treatment. Its core strategy involves leveraging the immune system to precisely target and attack cancer cells while minimizing damage to healthy tissue. A key candidate in its clinical pipeline is IMC-002, a fully human anti-CD47 monoclonal antibody under development for various malignancies. ImmuneOncia actively engages in strategic partnerships to accelerate its drug development programs, aiming to provide new therapeutic options for cancer patients.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 95% confidence The document is a ‘주식등의 대량보유상황보고서’ (Report on the status of large shareholding) under Korea’s Capital Markets Act, detailing share counts, ownership ratios, acquisition methods, dates and fund sources. This corresponds exactly to a Major Shareholding Notification (MRQ).
2026-05-27 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 85% confidence The document is a regulatorily mandated ‘Ownership Status Report of Specific Securities by Executives and Major Shareholders,’ filed with the Korean Securities & Futures Commission and Korea Exchange. It details insider holdings, changes in share count, acquisition dates, and transaction specifics for directors, officers, and major shareholders. This matches the definition of a Director’s Dealing report, which covers personal share transactions and changes in ownership by company executives and directors. It is not a mere announcement of a report or a general regulatory notice but the actual insider transaction/ownership report itself.
2026-05-27 Korean
증권발행실적보고서
Share Issue/Capital Change Classification · 89% confidence The document is a detailed “증권발행실적보고서” (Securities Issuance Performance Report) filed to the Korean Financial Supervisory Service, outlining a rights offering/new share issuance: subscription schedules, allocation details, use of proceeds, post-issuance share counts, and changes in major shareholders’ percentages. This corresponds to an announcement and report on new share issuance and capital change. Therefore, the appropriate category is Share Issue/Capital Change (SHA).
2026-05-21 Korean
증권발행결과(자율공시)
Share Issue/Capital Change Classification · 97% confidence The document is a voluntary disclosure detailing the results of a share issuance (rights offering) by the company, including share counts, amounts, payment dates and listing schedule. This falls squarely under announcements of new share issues or capital changes rather than a full report or call transcript. Therefore, it is classified as a Share Issue/Capital Change (SHA).
2026-05-21 Welsh
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is titled “분기보고서” (Quarterly Report) covering the period January 1, 2026 to March 31, 2026. It runs over 112,000 characters, contains detailed narrative on business overview, product pipelines, and actual quarterly financial data (sales, cost tables, contract terms, R&D spend, etc.). It is not merely an announcement of a report, but the full interim report itself. Therefore, it is classified as an Interim/Quarterly Report (IR). Q1 2026
2026-05-15 Korean
[기재정정]분기보고서 (2026.03)
Interim / Quarterly Report Classification · 88% confidence The document is titled “분기보고서” (Quarterly Report) and covers the company’s financial statements for the 11th fiscal period 1Q (2026-01-01 to 2026-03-31), including the balance sheet, income statement, statement of changes in equity, and cash flow statement. Although it is a correction filing (“정정신고”), it contains the full, substantive financial data rather than merely announcing or linking to a separate report. Under our definitions, this qualifies as an Interim/Quarterly Report. Q1 2026
2026-05-15 Korean

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.